Genentech Enters into an Exclusive Worldwide Collaboration and Option to Acquire Agreement with Convelo to Discover Remyelinating Therapies

 Genentech Enters into an Exclusive Worldwide Collaboration and Option to Acquire Agreement with Convelo to Discover Remyelinating Therapies

Genentech, Enters, Exclusive, Worldwide, Collaboration, Option, Acquire, Agreement, Convelo, Discover, Remyelinating Therapies

Shots:

  • Genentech & Convelo collaborate to discover and develop remyelination therapies for patients with neurological disorders including multiple sclerosis
  • Convelo to receive up front and research support from Genentech. Genentech to retain an exclusive option to acquire Convelo in all-stock transaction for additional payment and downstream milestones
  • Remyelinating therapies are involved in unlocking the regenerative capacity of the CNS by generating the protective myelin coating around nerve cells for neurological diseases like MS, pediatric leukodystrophies, traumatic injury and Alzheimer’s

Click here to read full press release/ article | Ref: Convelo | Image: Convelo

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post